Search - tctmd.com

Displaying 21 - 30 of 30

Sort: Relevancy | Date

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

January 13, 2023

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

June 23, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

December 17, 2020

TCTMD’s Top 10 Most Popular Stories for August 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2020

August 28, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.